First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)

被引：0
|
作者：
Ravaud, A.
Oudard, S.
Gravis-Mescam, G.
Sevin, E.
Zanetta, S.
Theodore, C.
de Fromont, M.
Oukhatar, C. Mahier-Ait
Chene, G.
Escudier, B.
机构：
[1] CHU Bordeaux, Hosp St Andre, Bordeaux, France
[2] Hop Europeen Georges Pompidou, Paris, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Ctr Georges Francois Leclerc, Dijon, France
[6] Hop Foch, Suresnes, France
[7] FNCLCC, Paris, France
[8] ISPED, Bordeaux, France
[9] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
    Rodriguez-Vida, Alejo
    Bamias, Aristotelis
    Esteban, Emilio
    Isabel Saez, Maria
    Lopez-Brea, Marta
    Castellano, Daniel
    Caballero, Cristina
    Luis Gonzalez-Larriba, Jose
    Calvo, Emiliano
    Macia, Sonia
    Ravaud, Alain
    Bellmunt, Joaquim
    BJU INTERNATIONAL, 2020, 126 (05) : 559 - 567
  • [32] Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
    Oya, Mototsugu
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Shinohara, Nobuo
    Habuchi, Tomonori
    Rini, Brian I.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Bair, Angel H.
    Uemura, Hirotsugu
    CANCER SCIENCE, 2017, 108 (06): : 1231 - 1239
  • [33] The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma - A Phase II study of the Hellenic Cooperative Oncology Group
    Bamias, A
    Moulopoulos, LA
    Koutras, A
    Aravantinos, G
    Fountzilas, G
    Pectasides, D
    Kastritis, E
    Gika, D
    Skarlos, D
    Linardou, H
    Kalofonos, HP
    Dimopoulos, MA
    CANCER, 2006, 106 (02) : 297 - 303
  • [34] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, Mian
    He, Chaosheng
    Huang, Jinkun
    Lin, Qizhan
    Zou, Lixin
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [35] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, M.
    He, C.
    Huang, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 71 - 71
  • [36] OPEN-LABEL PHASE II TRIAL OF FIRST-LINE EVEROLIMUS MONOTHERAPY IN PATIENTS WITH ADVANCED PAPILLARY RENAL CELL CARCINOMA: RAPTOR INTERIM ANALYSIS
    Escudier, B.
    Bracarda, S.
    Maroto, J. P.
    Szczylik, C.
    Nathan, P.
    Negrier, S.
    Slimane, K.
    May, C.
    Porta, C.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 264 - 264
  • [37] Re: Randomized Phase II Trial of Sunitinib on an Intermittent versus Continuous Dosing Schedule as First-Line Therapy for Advanced Renal Cell Carcinoma Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (02): : 413 - 414
  • [38] Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
    Escudier, B.
    Bracarda, S.
    Maroto, J. P.
    Szczylik, C.
    Nathan, P.
    Negrier, S.
    Castellano, D.
    Weiss, C.
    Porta, C.
    Gruenwald, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S643 - S643
  • [39] Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results
    Barrios, C. H.
    Hernandez-Barajas, D.
    Brown, M. P.
    Lee, S. H.
    Fein, L.
    Liu, J. H.
    Hariharan, S.
    Martell, B.
    Yuan, J.
    Rha, S. Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 429 - 430
  • [40] Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group
    Sutton, G
    Axelrod, JH
    Bundy, BN
    Roy, T
    Homesley, H
    Lee, RB
    Gehrig, PA
    Zaino, R
    GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 349 - 354
12345